Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerstin Westermark

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|November 29, 2012
Promoting the development of drugs against rare diseases: what more should be done?Kerstin Westermark, Jordi Llinares
BMJ (Clinical Research Ed.)|January 13, 2011
Orphan drugs. EU regulationsSegundo Mariz, Jordi Llinares, Kerstin Westermark
Upsala Journal of Medical Sciences|October 12, 2020
Remarkable developments in our performanceArne Andersson, Joey Lau Börjesson, Kerstin Westermark
Nordic Journal of Psychiatry|December 10, 2002
Sleep in patients with treated Wilson's disease. A questionnaire studyKamilla Portala, Kerstin Westermark, Lisa Ekselius, et al.
Upsala Journal of Medical Sciences|June 4, 2008
Psychopathology and personality traits in patients with treated Wilson disease grouped according to gene mutationsKamilla Portala, Erik Waldenström, Lars von Knorring, et al.
International Journal of Cancer|February 22, 2002
Collagen type I expression in experimental anaplastic thyroid carcinoma: regulation and relevance for tumorigenicityThèrése Dahlman, Ellen Lammerts, Daniel Bergström, et al.
Nature Reviews. Drug Discovery|March 16, 2013
Animal models for metabolic, neuromuscular and ophthalmological rare diseasesGuillaume Vaquer, Frida Rivière, Maria Mavris, et al.
Orphanet Journal of Rare Diseases|October 8, 2015
Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European UnionStelios Tsigkos, Segundo Mariz, Jordi Llinares, et al.
Nature Reviews. Drug Discovery|June 2, 2016
Worldwide collaboration for orphan drug designationSegundo Mariz, James H Reese, Kerstin Westermark, et al.
Orphanet Journal of Rare Diseases|December 6, 2014
Establishing medical plausibility in the context of orphan medicines designation in the European UnionStelios Tsigkos, Segundo Mariz, Jordi Llinares, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Review of Pharmacoeconomics & Outcomes Research|November 29, 2012
Promoting the development of drugs against rare diseases: what more should be done?Kerstin Westermark, Jordi Llinares
BMJ (Clinical Research Ed.)|January 13, 2011
Orphan drugs. EU regulationsSegundo Mariz, Jordi Llinares, Kerstin Westermark
Upsala Journal of Medical Sciences|October 12, 2020
Remarkable developments in our performanceArne Andersson, Joey Lau Börjesson, Kerstin Westermark
Nordic Journal of Psychiatry|December 10, 2002
Sleep in patients with treated Wilson's disease. A questionnaire studyKamilla Portala, Kerstin Westermark, Lisa Ekselius, et al.
Upsala Journal of Medical Sciences|June 4, 2008
Psychopathology and personality traits in patients with treated Wilson disease grouped according to gene mutationsKamilla Portala, Erik Waldenström, Lars von Knorring, et al.
International Journal of Cancer|February 22, 2002
Collagen type I expression in experimental anaplastic thyroid carcinoma: regulation and relevance for tumorigenicityThèrése Dahlman, Ellen Lammerts, Daniel Bergström, et al.
Nature Reviews. Drug Discovery|March 16, 2013
Animal models for metabolic, neuromuscular and ophthalmological rare diseasesGuillaume Vaquer, Frida Rivière, Maria Mavris, et al.
Orphanet Journal of Rare Diseases|October 8, 2015
Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European UnionStelios Tsigkos, Segundo Mariz, Jordi Llinares, et al.
Nature Reviews. Drug Discovery|June 2, 2016
Worldwide collaboration for orphan drug designationSegundo Mariz, James H Reese, Kerstin Westermark, et al.
Orphanet Journal of Rare Diseases|December 6, 2014
Establishing medical plausibility in the context of orphan medicines designation in the European UnionStelios Tsigkos, Segundo Mariz, Jordi Llinares, et al.
Pageof 2